Soricimed developed their blood test to detect the presence of TRPV6 messenger RNA, a biomarker identified as being present in many epithelially derived cancers. The test has been shown to detect a host of cancers, including ovarian, breast and prostate, at their earliest stages.
Working in partnership with the Dr. Georges-L.-Dumont University Hospital Centre, a member institution of the Vitalite Health Network, located in Moncton, NB, Soricimed has initiated a blood sampling project to collect samples from up to 700 patients.
"We have been able to isolate a marker from human blood plasma which, in cancer patients, shows a fingerprint of the cancer", commented Professor Jack Stewart, Chief Scientific Officer at Soricimed Biopharma. "It's like an early warning system that alerts physicians to the presence of cancer."
"Half the battle with cancer is being able to detect it early enough to save lives", stated Elisabeth Ross, Chief Executive Officer, Ovarian Cancer Canada. "In the case of ovarian cancer, there are no early symptoms and currently no screening tests available so it's not usually detected until Stage Three or Four. As a result, the mortality rate is extremely high, with - 70% of women not surviving more than five years. If ovarian cancer could be detected at Stage One, we could dramatically increase survival rates."
"We are thrilled to be part of the research continuum that moves novel discoveries into the clinical practice, in hopes of improving the health outcomes of our population. The success of this project is the result of a great collaboration with Soricimed Biopharma Inc., our clinicians and multidisciplinary teams at the Dr. Georges-L.-Dumont University Hospital Centre", stated Gilles Beaulieu, Vice-President, Academic Affairs and Research at Vitalite Health Network.
The study is expected to be completed late Fall of this year. Based on successful results, Soricimed Biopharma would move the test through the regulatory approval process which could result in an approved diagnostic being available for use within 24 months. Testing for cancer could become just another box to check on a person's regular physical examination.